Do histone deacytelase inhibitors and azacitidine combination hold potential as an effective treatment for high/very-high risk myelodysplastic syndromes?

References

• Strom SS, Vélez-Bravo V, Estey EH. Epidemiology of Myelodysplastic Syndromes. Semin Hematol. 2008;45(1):8–13.
   PubMed Web of Science ®Google Scholar
• Badar T, Szabo A, Sallman D, et al. Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. Leuk Lymphoma. 2020;61(6):1418–1427.
   PubMed Web of Science ®Google Scholar
• Badar T, Patel KP, Thompson PA, et al. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res. 2015;39(12):1367–1374.
   PubMed Web of Science ®Google Scholar
• Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Platzbecker U, Ades L. How we manage adults with myelodysplastic syndrome. Br J Haematol. 2020;189(6):1016–1027.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109(1):52–57.
   PubMed Web of Science ®Google Scholar
• Atallah E, Logan B, Chen M, et al. Comparison of patient age groups in transplantation for myelodysplastic syndrome: the medicare coverage with evidence development study. JAMA Oncol. 2019;6(4):486–493.
   Web of Science ®Google Scholar
• De Ruijter AJ, Van Gennip AH, Caron HN, et al. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370(Pt3):737–749.
   PubMedGoogle Scholar
• Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002;1(4):287–299.
   PubMed Web of Science ®Google Scholar
• Yang H, Hoshino K, Sanchez-Gonzalez B, et al. Antileukemia activity of the combination of 5-aza-2ʹ-deoxycytidine with valproic acid. Leuk Res. 2005;29(7):739–748.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Abaza Y, Takahashi K, et al. Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. Blood Adv. 2019;3(4):508–518.
   PubMed Web of Science ®Google Scholar
• Badar T, Guru Murthy GS, Runaas L, et al. Phase I study of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed/refractory Acute Myeloid Leukemia (AML). Blood. 2019;134(Supplement_1):5068.
   Google Scholar
• Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med. 2001;134(7):573–586.
   PubMed Web of Science ®Google Scholar
• Keating GM. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia. Drugs. 2012;72(8):1111–1136.
   PubMed Web of Science ®Google Scholar
• Leone G, Teofili L, Voso MT, et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica. 2002;87(12):1324–1341.
   PubMed Web of Science ®Google Scholar
• Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009;23(6):1019–1028.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Silverman L, Eller M, et al. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol. 2005;45(5):597–602.
   PubMed Web of Science ®Google Scholar
• Laille E, Goel S, Mita AC, et al. A phase I study in patients with solid or hematologic malignancies of the dose proportionality of subcutaneous Azacitidine and its pharmacokinetics in patients with severe renal impairment. Pharmacotherapy. 2014;34(5):440–451.
   PubMed Web of Science ®Google Scholar
• Chen Y, Liu L, Laille E, et al. In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine. Cancer Chemother Pharmacol. 2010;65(5):995–1000.
   PubMed Web of Science ®Google Scholar
• Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20(10):2429–2440.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–232.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Thépot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117(2):403–411.
   PubMed Web of Science ®Google Scholar
• Vidal V, Robert G, Goursaud L, et al. BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. Oncotarget. 2017;8(29):47103–47109.
   PubMedGoogle Scholar
• Unnikrishnan A, Papaemmanuil E, Beck D, et al. Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes. Cell Rep. 2017;20(3):572–585.
   PubMed Web of Science ®Google Scholar
• Cai J, Wei H, Hong KH, et al. Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents. Bioorg Med Chem. 2015;23(13):3457–3471.
   PubMed Web of Science ®Google Scholar
• Abaza YM, Kadia TM, Jabbour EJ, et al. Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies. Cancer. 2017;123(24):4851–4859.
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6(1):38–51.
   PubMed Web of Science ®Google Scholar
• Göttlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo J. 2001;20(24):6969–6978.
   PubMed Web of Science ®Google Scholar
• Kelly WK, O’Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005;23(17):3923–3931.
   PubMed Web of Science ®Google Scholar
• Jayaraman R, Pilla Reddy V, Pasha MK, et al. Preclinical metabolism and disposition of SB939 (Pracinostat), an orally active histone deacetylase inhibitor, and prediction of human pharmacokinetics. Drug Metab Dispos. 2011;39(12):2219–2232.
   PubMed Web of Science ®Google Scholar
• Novotny-Diermayr V, Sangthongpitag K, Hu CY, et al. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther. 2010;9(3):642–652.
   PubMed Web of Science ®Google Scholar
• Novotny-Diermayr V, Sausgruber N, Loh YK, et al. Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue. Mol Cancer Ther. 2011;10(7):1207–1217.
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Knipp S, Fox F, et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol. 2005;84(Suppl 1):61–66.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111(3):1060–1066.
   PubMed Web of Science ®Google Scholar
• Razak AR, Hotte SJ, Siu LL, et al. Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours. Br J Cancer. 2011;104(5):756–762.
   PubMed Web of Science ®Google Scholar
• Cameron EE, Bachman KE, Myöhänen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21(1):103–107.
   PubMed Web of Science ®Google Scholar
• Issa J-P, Garcia-Manero G, Huang X, et al. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015;121(4):556–561.
   PubMed Web of Science ®Google Scholar
• Odenike O, Halpern A, Godley LA, et al. A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia. Investig N Drugs. 2015;33(2):371–379. .
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Sekeres MA, Egyed M, et al. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts. Leukemia. 2017;31(12):2799–2806.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Othus M, List AF, et al. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017;35(24):2745–2753.
   PubMed Web of Science ®Google Scholar
• Yalniz FF, Berdeja JG, Maris MB, et al. A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. Br J Haematol. 2020;188(3):404–412.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Montalban-Bravo G, Berdeja JG, et al. Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes. Cancer. 2017;123(6):994–1002.
   PubMed Web of Science ®Google Scholar
• Atallah EL, Khaled SK, Cooper BW, et al. Phase II study of lower-dose pracinostat plus azacitidine safety and efficacy in patients with high/very high-risk myelodysplastic syndromes. J Clin Oncol. 2020;38(15_suppl):7556.
   Web of Science ®Google Scholar
• Atallah E, Logan B, Chen M, et al. Comparison of patient age groups in transplantation for myelodysplastic syndrome: the medicare coverage with evidence development study. JAMA Oncol. 2020;6(4):486–493.
   PubMed Web of Science ®Google Scholar
• https://www.helsinn.com/news-and-events/helsinn-group-and-mei-pharma-discontinue-the-phase-3-study-with-pracinostat-in-aml-after-completing-interim-analysis.
   Google Scholar
• Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011;29(24):3322–3327.
   PubMed Web of Science ®Google Scholar
• Tan P, Wei A, Mithraprabhu S, et al. Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Cancer J. 2014;4(1):e170.
   PubMed Web of Science ®Google Scholar
• Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110(7):2302–2308.
   PubMed Web of Science ®Google Scholar
• Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705–2712.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Patel K, Bueso-Ramos C, et al. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 2016;7(12):14172–14187.
   PubMedGoogle Scholar